Table 2: Recent evidence confirming the anti-cancer effects of aspirin. Summary of observational data assessing the effect of aspirin after a cancer diagnosis by tumour type. OS overall survival, HR hazard ratio, RR relative risk, estimates given with 95% confidence intervals, $ data not available for OS, * data not available for cancer specific mortality.
| Tumour | Study/Year/Reference | Result (in favour of aspirin) |
|---|---|---|
| Colorectal (CRC) | Chan 2009 [16] | CRC mortality HR 0.71 (0.53–0.95) OS HR 0.79 (0.65-0.97) |
| Bastiaannet 2012 [17] | OS RR 0.65 (0.50 - 0.84) | |
| McCowan 2012 [18] | CRC mortality HR 0.67 (0.57-0.79) OS HR 0.58 (0.45-0.75) |
|
| Breast (BC) | Holmes 2010 [15] | BC mortality RR 0.36 (0.24–0.65) OS RR 0.54 (0.41-0.70) |
| Prostate (PC) | Zaorsky 2012 [19] | Reduced interval to biochemical failure – aspirin non-use OR 2.05 (1.33-3.17) |
| Choe 2012 [20] | PC mortality HR 0.43 (0.21-0.87)$ | |
| Gastric Oesophagus | Liu 2009 [21] | 5 year OS aspirin 51.2%, placebo 41%, no tablet 42.3%* |